"Absorb is a leading example of Abbott's dedication to advancing patient outcomes through innovative technology. Abbott has remained committed to meeting the growing physician and patient demand for a bioresorbable vascular scaffold – from the initial device developed nearly 10 years ago to the expansion of our manufacturing capabilities to support this international launch," said John M. Capek, executive vice president, Medical Devices, Abbott. "We are proud to be the first company to commercialize a drug eluting bioresorbable vascular scaffold, which has the potential to revolutionize the way physicians treat their patients with coronary artery disease."Heart disease is the leading cause of death for men and women around the world, and CAD is the most common type of heart disease. 1,2 CAD occurs when arteries that supply blood to the heart become narrowed or blocked, leading to chest pain or shortness of breath and increased risk of heart attack.
Abbott Announces International Launch Of The Absorb™ Bioresorbable Vascular Scaffold
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts